Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 3
2012 2
2013 1
2014 6
2015 1
2016 6
2017 8
2018 8
2019 3
2020 4
2021 5
2022 4
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Sorafenib for Advanced and Refractory Desmoid Tumors.
Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Gounder MM, et al. Among authors: milhem mm. N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052. N Engl J Med. 2018. PMID: 30575484 Free PMC article. Clinical Trial.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. de la Fuente MI, et al. Among authors: milhem mm. Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139. Neuro Oncol. 2023. PMID: 35639513 Free PMC article. Clinical Trial.
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Ribas A, et al. Among authors: milhem mm. Cancer Discov. 2021 Dec 1;11(12):2998-3007. doi: 10.1158/2159-8290.CD-21-0425. Cancer Discov. 2021. PMID: 34326162 Free PMC article. Clinical Trial.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. D'Angelo SP, et al. Among authors: milhem mm. Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19. Lancet Oncol. 2018. PMID: 29370992 Free PMC article. Clinical Trial.
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. Chesney JA, et al. Among authors: milhem mm. J Immunother Cancer. 2023 May;11(5):e006270. doi: 10.1136/jitc-2022-006270. J Immunother Cancer. 2023. PMID: 37142291 Free PMC article. Clinical Trial.
Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.
Rytlewski J, Milhem MM, Monga V. Rytlewski J, et al. Among authors: milhem mm. Ann Transl Med. 2021 Jun;9(12):1039. doi: 10.21037/atm-20-6041. Ann Transl Med. 2021. PMID: 34277839 Free PMC article. Review.
Surgical management for giant bladder leiomyosarcoma.
Hart AA, Schlaepfer CH, Dhungana N, Milhem MM, Packiam VT. Hart AA, et al. Among authors: milhem mm. Urol Case Rep. 2022 Jan 7;42:101995. doi: 10.1016/j.eucr.2022.101995. eCollection 2022 May. Urol Case Rep. 2022. PMID: 35059300 Free PMC article.
Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents.
Callaghan CM, Hasibuzzaman MM, Rodman SN, Goetz JE, Mapuskar KA, Petronek MS, Steinbach EJ, Miller BJ, Pulliam CF, Coleman MC, Monga VV, Milhem MM, Spitz DR, Allen BG. Callaghan CM, et al. Among authors: milhem mm. Cancers (Basel). 2020 Aug 12;12(8):2258. doi: 10.3390/cancers12082258. Cancers (Basel). 2020. PMID: 32806601 Free PMC article. Review.
50 results